AI assistant
Q/C TECHNOLOGIES, INC. — Regulatory Filings 2020
Mar 23, 2020
35313_rns_2020-03-23_e91049a7-5b18-4308-9674-aca36199e828.zip
Regulatory Filings
Open in viewerOpens in your device viewer
CORRESP 1 filename1.htm
Akers Biosciences, Inc.
201 Grove Road
Thorofare, New Jersey 08086
March 23, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Securities and Exchange Commission
Washington, D.C. 20549
Attention: Paul Fischer
| Re: |
|---|
| Registration |
| Statement on Form S-3, originally filed on November 1, 2019 |
| File |
| No. 333-234449 (the “ Registration Statement ”) |
| Request |
| for Acceleration |
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “ Commission ”) under the Securities Act of 1933, as amended, Akers Biosciences, Inc. (the “ Company ”) hereby respectfully requests acceleration of the effective date of the Registration Statement so that it may become effective at 4:00 p.m., Eastern Time, on March 24, 2020, or as soon thereafter as practicable.
Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
| Very
| truly yours, | |
|---|---|
| AKERS | |
| BIOSCIENCES, INC. | |
| By: | /s/ |
| Christopher Schreiber | |
| Christopher | |
| Schreiber Executive Chairman of the Board of Directors and Director |
cc: Rick A. Werner, Esq., Haynes and Boone, LLP
Field: Page; Sequence: 1
Field: /Page